Aldosterone
Galectin-3 may modify CV mortality risk via aldosterone
Galectin-3 interacted with risk for fatal CV events associated with aldosterone in patients referred for coronary angiography, according to a study published in The American Journal of Cardiology.
Mineralocorticoids show utility as type 2 diabetes, prediabetes biomarkers
Elevated levels of the mineralocorticoids aldosterone and 11-deoxycorticosterone were associated with prediabetes and type 2 diabetes among adult participants in the Rural Henan Cohort study, according to findings published in the Journal of Diabetes and its Complications.
Adequate timing key for biochemical evaluation after unilateral adrenalectomy
A biochemical evaluation to determine the success of unilateral adrenalectomy among adults with an aldosterone-producing adenoma should occur no sooner than 3 months after surgery, due in part to early postsurgical changes in active renin concentration, according to findings published in Clinical Endocrinology.
Basal plasma aldosterone predicts therapeutic outcomes in primary aldosteronism
Baseline plasma aldosterone concentration is independently associated with clinical and biochemical outcomes of treatment among adults with primary aldosteronism, and data suggest that mineralocorticoid receptor antagonist therapy is the optimal strategy vs. adrenalectomy for those with a normal plasma aldosterone concentration, according to findings published in the Journal of the Endocrine Society.
Part of the Healio Network
ACE Inhibitors
Angiotensin converting enzyme inhibitors are a class of oral medications that act primarily through blockade of the angiotensin converting enzyme.
Part of the Healio Network
Aldosterone Antagonists
Aldosterone antagonists (spironolactone, eplerenone) also known as “potassium sparing diuretics” block the action of aldosterone inhibiting the reuptake of sodium and water.
Part of the Healio Network
Eplerenone
Eplerenone is an aldosterone antagonist, also known as a “potassium sparing diuretic.”